O	0	11	Feasibility
O	12	17	study
O	18	20	of
B-intervention	21	30	docetaxel
I-intervention	31	34	and
I-intervention	35	51	cyclophosphamide
I-intervention	52	55	six
I-intervention	55	56	-
I-intervention	57	62	cycle
I-intervention	63	70	therapy
O	71	73	as
O	74	82	adjuvant
O	83	95	chemotherapy
O	96	99	for
B-ethinicity	100	108	Japanese
B-eligibility	109	114	human
I-eligibility	115	124	epidermal
I-eligibility	125	131	growth
I-eligibility	132	138	factor
I-eligibility	139	147	receptor
I-eligibility	148	149	2
I-eligibility	149	150	-
I-eligibility	150	158	negative
I-eligibility	159	165	breast
I-eligibility	166	172	cancer
I-eligibility	173	181	patients
O	181	182	.

O	183	185	We
O	186	194	compared
O	195	204	treatment
O	205	215	completion
O	216	221	rates
O	222	225	and
O	226	232	safety
O	233	235	of
O	236	245	docetaxel
O	246	249	and
O	250	266	cyclophosphamide
O	267	270	six
O	270	271	-
O	272	277	cycle
O	278	285	therapy
O	286	287	(
O	287	290	TC6
O	290	291	)
O	292	296	with
O	297	306	docetaxel
O	307	315	followed
O	316	318	by
O	319	322	5FU
O	322	323	,
O	324	334	epirubicin
O	335	338	and
O	339	355	cyclophosphamide
O	356	357	(
B-control	357	358	T
I-control	358	359	-
I-control	359	362	FEC
O	362	363	)
O	364	371	therapy
O	372	374	in
O	375	383	Japanese
O	384	392	patients
O	393	397	with
O	398	403	human
O	404	413	epidermal
O	414	420	growth
O	421	427	factor
O	428	436	receptor
O	437	438	2
O	439	440	(
O	440	444	HER2
O	444	445	)
O	445	446	-
O	446	454	negative
O	455	461	breast
O	462	468	cancer
O	468	469	.

O	470	472	We
O	473	485	administered
O	486	489	TC6
O	490	493	q3w
O	494	496	or
O	497	498	T
O	498	499	-
O	499	502	FEC
O	503	506	q3w
O	507	509	to
O	510	514	HER2
O	514	515	-
O	515	523	negative
O	524	530	breast
O	531	537	cancer
O	538	546	patients
O	546	547	.

O	548	551	The
O	552	559	primary
O	560	568	endpoint
O	569	571	of
O	572	576	this
O	577	582	trial
O	583	586	was
B-outcome-Measure	587	595	toxicity
O	595	596	.

O	597	599	As
O	600	606	second
O	607	616	endpoints
O	616	617	,
O	618	621	the
B-outcome-Measure	622	631	treatment
I-outcome-Measure	632	642	completion
I-outcome-Measure	643	647	rate
O	648	651	and
B-outcome-Measure	652	660	relative
I-outcome-Measure	661	665	dose
I-outcome-Measure	666	675	intensity
O	676	680	were
O	681	690	evaluated
O	690	691	.

O	692	695	The
O	696	699	TC6
O	700	703	and
O	704	705	T
O	705	706	-
O	706	709	FEC
O	710	715	group
O	716	725	consisted
O	726	728	of
B-intervention-participants	729	731	22
O	732	735	and
B-control-participants	736	738	21
O	739	747	patients
O	747	748	,
O	749	761	respectively
O	761	762	.

O	763	773	Concerning
O	774	787	hematological
O	788	796	toxicity
O	796	797	,
B-outcome	798	803	grade
I-outcome	804	805	3
I-outcome	806	808	or
I-outcome	809	815	higher
I-outcome	816	823	adverse
I-outcome	824	833	reactions
O	834	842	included
B-outcome	843	854	neutropenia
I-outcome	855	858	and
I-outcome	859	866	febrile
I-outcome	867	878	neutropenia
O	878	879	.

O	880	882	As
O	883	886	non
O	886	887	-
O	887	900	hematological
O	901	908	adverse
O	909	915	events
O	915	916	,
O	917	926	exanthema
O	927	930	and
O	931	941	peripheral
O	942	952	neuropathy
O	953	957	were
O	958	968	frequently
O	969	977	reported
O	978	980	in
O	981	984	the
O	985	988	TC6
O	989	994	group
O	994	995	,
O	996	1003	whereas
O	1004	1008	more
O	1009	1017	patients
O	1018	1020	of
O	1021	1024	the
O	1025	1026	T
O	1026	1027	-
O	1027	1030	FEC
O	1031	1036	group
O	1037	1045	reported
O	1046	1052	nausea
O	1053	1056	and
O	1057	1065	vomiting
O	1065	1066	.

O	1067	1069	In
O	1070	1073	TC6
O	1073	1074	,
O	1075	1078	the
B-outcome	1079	1088	treatment
I-outcome	1089	1099	completion
I-outcome	1100	1104	rate
O	1105	1108	was
B-iv-bin-percent	1109	1111	86
I-iv-bin-percent	1111	1112	.
I-iv-bin-percent	1112	1113	4
I-iv-bin-percent	1113	1114	%
O	1115	1118	and
O	1119	1122	the
O	1123	1131	relative
O	1132	1136	dose
O	1137	1146	intensity
O	1147	1149	of
O	1150	1159	docetaxel
O	1160	1163	was
B-iv-bin-percent	1164	1166	93
I-iv-bin-percent	1166	1167	.
I-iv-bin-percent	1167	1168	2
I-iv-bin-percent	1168	1169	%
O	1169	1170	.

O	1171	1173	In
O	1174	1175	T
O	1175	1176	-
O	1176	1179	FEC
O	1179	1180	,
O	1181	1184	the
O	1185	1191	values
O	1192	1196	were
B-cv-bin-percent	1197	1199	95
I-cv-bin-percent	1199	1200	.
I-cv-bin-percent	1200	1201	2
I-cv-bin-percent	1201	1202	%
O	1203	1206	and
B-cv-bin-percent	1207	1209	98
I-cv-bin-percent	1209	1210	.
I-cv-bin-percent	1210	1211	9
I-cv-bin-percent	1211	1212	%
O	1212	1213	,
O	1214	1226	respectively
O	1226	1227	.

O	1228	1233	These
O	1234	1241	results
O	1242	1249	suggest
O	1250	1254	that
O	1255	1258	TC6
O	1259	1261	is
O	1262	1271	tolerable
O	1272	1274	in
O	1275	1283	Japanese
O	1283	1284	,
O	1285	1288	and
O	1289	1293	that
O	1294	1298	this
O	1299	1306	regimen
O	1307	1310	can
O	1311	1315	also
O	1316	1318	be
O	1319	1328	performed
O	1329	1331	in
O	1332	1342	outpatient
O	1343	1350	clinics
O	1350	1351	.

O	1352	1359	However
O	1359	1360	,
O	1361	1365	with
O	1366	1369	the
O	1370	1373	TC6
O	1374	1381	regimen
O	1381	1382	,
O	1383	1386	the
O	1387	1397	compliance
O	1398	1401	was
O	1402	1410	slightly
O	1411	1416	lower
O	1417	1421	than
O	1422	1426	with
O	1427	1430	the
O	1431	1432	T
O	1432	1433	-
O	1433	1436	FEC
O	1437	1444	regimen
O	1444	1445	,
O	1446	1449	and
O	1450	1460	supportive
O	1461	1468	therapy
O	1469	1474	needs
O	1475	1477	to
O	1478	1480	be
O	1481	1488	managed
O	1489	1502	appropriately
O	1502	1503	.
